MODERNA INC (MRNA)
US60770K1079 - Common Stock
Overall MRNA gets a fundamental rating of 3 out of 10. We evaluated MRNA against 588 industry peers in the Biotechnology industry. MRNA scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. MRNA is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year MRNA has reported negative net income.
In the past year MRNA has reported a negative cash flow from operations.
In multiple years MRNA reported negative net income over the last 5 years.
The reported operating cash flow has been mixed in the past 5 years: MRNA reported negative operating cash flow in multiple years.
1.2 Ratios
The Return On Assets of MRNA (-25.58%) is better than 76.24% of its industry peers.
Looking at the Return On Equity, with a value of -34.03%, MRNA is in the better half of the industry, outperforming 77.95% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -25.58% | ||
| ROE | -34.03% | ||
| ROIC | N/A |
ROA(3y)18.74%
ROA(5y)2.74%
ROE(3y)31.99%
ROE(5y)4.61%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Gross Margin of MRNA (31.47%) is better than 77.09% of its industry peers.
MRNA's Gross Margin has declined in the last couple of years.
The Profit Margin and Operating Margin are not available for MRNA so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 31.47% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-31.75%
GM growth 5YN/A
2. Health
2.1 Basic Checks
MRNA does not have a ROIC to compare to the WACC, probably because it is not profitable.
MRNA has less shares outstanding than it did 1 year ago.
Compared to 5 years ago, MRNA has more shares outstanding
MRNA has a better debt/assets ratio than last year.
2.2 Solvency
An Altman-Z score of 6.25 indicates that MRNA is not in any danger for bankruptcy at the moment.
With an excellent Altman-Z score value of 6.25, MRNA belongs to the best of the industry, outperforming 82.73% of the companies in the same industry.
MRNA has a Debt/Equity ratio of 0.04. This is a healthy value indicating a solid balance between debt and equity.
MRNA has a Debt to Equity ratio (0.04) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.04 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 6.25 |
ROIC/WACCN/A
WACC9.12%
2.3 Liquidity
MRNA has a Current Ratio of 3.42. This indicates that MRNA is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of MRNA (3.42) is worse than 61.37% of its industry peers.
MRNA has a Quick Ratio of 3.36. This indicates that MRNA is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of MRNA (3.36) is worse than 60.51% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.42 | ||
| Quick Ratio | 3.36 |
3. Growth
3.1 Past
MRNA shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -162.17%.
The Revenue for MRNA has decreased by -64.45% in the past year. This is quite bad
MRNA shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 119.30% yearly.
EPS 1Y (TTM)-162.17%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q-84.76%
Revenue 1Y (TTM)-64.45%
Revenue growth 3Y104.31%
Revenue growth 5Y119.3%
Revenue growth Q2Q-44.71%
3.2 Future
Based on estimates for the next years, MRNA will show a very strong growth in Earnings Per Share. The EPS will grow by 25.22% on average per year.
MRNA is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 20.51% yearly.
EPS Next Y40.82%
EPS Next 2Y25.43%
EPS Next 3Y23.04%
EPS Next 5Y25.22%
Revenue Next Year-35.87%
Revenue Next 2Y-15.39%
Revenue Next 3Y-2.21%
Revenue Next 5Y20.51%
3.3 Evolution
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
MRNA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for MRNA. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
MRNA's earnings are expected to grow with 23.04% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y25.43%
EPS Next 3Y23.04%
5. Dividend
5.1 Amount
No dividends for MRNA!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
MODERNA INC
NASDAQ:MRNA (4/18/2024, 7:09:06 PM)
After market: 101.75 -0.25 (-0.25%)102
-1.44 (-1.39%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap39.05B
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -25.58% | ||
| ROE | -34.03% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 31.47% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.37
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.04 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 3.42 | ||
| Quick Ratio | 3.36 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)-162.17%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y40.82%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-64.45%
Revenue growth 3Y104.31%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y